within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR01_ZidovudineAndLamivudine;

model ZidovudineAndLamivudine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.65,
    Cl = 3.111111111111112e-05,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.0016,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016666666666666666,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>ZidovudineAndLamivudine</td></tr><tr><td>ATC code:</td><td>J05AR01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.6</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Zidovudine and lamivudine are antiretroviral medications combined to treat HIV-1 infection. Both are nucleoside reverse transcriptase inhibitors (NRTIs) and are used as a backbone in combination antiretroviral therapy (ART). The fixed-dose combination is approved and widely used today for the management of HIV infection.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for zidovudine and lamivudine following oral administration in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Zhou, XJ, et al., &amp; Sommadossi, JP (2000). Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. <i>AIDS (London, England)</i> 14(18) 2869–2876. DOI:<a href=\"https://doi.org/10.1097/00002030-200012220-00008\">10.1097/00002030-200012220-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11153668/\">https://pubmed.ncbi.nlm.nih.gov/11153668</a></p></li><li><p>Anderson, PL, et al., &amp; Fletcher, CV (2006). Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. <i>Journal of acquired immune deficiency syndromes (1999)</i> 42(4) 441–449. DOI:<a href=\"https://doi.org/10.1097/01.qai.0000225013.53568.69\">10.1097/01.qai.0000225013.53568.69</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16791115/\">https://pubmed.ncbi.nlm.nih.gov/16791115</a></p></li><li><p>Bhana, N, et al., &amp; Figgitt, DP (2002). Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection. <i>Paediatric drugs</i> 4(8) 515–553. DOI:<a href=\"https://doi.org/10.2165/00128072-200204080-00004\">10.2165/00128072-200204080-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12126455/\">https://pubmed.ncbi.nlm.nih.gov/12126455</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AR01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end ZidovudineAndLamivudine;
